HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

diacetyldichlorofluorescein

stable storage form of dichlorofluorescein
Also Known As:
2',7'-dichlorofluorescein diacetate; 2',7'-dichlorofluorescin diacetate; 2',7'-difluorofluorescein; DCFDA; DCFH-DA; leuco-DCF diacetate; leukodiacetyl-2,7-dichlorofluorescein
Networked: 64 relevant articles (3 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Lang, Florian: 13 articles (08/2015 - 01/2012)
2. Alzoubi, Kousi: 8 articles (08/2015 - 01/2015)
3. Faggio, Caterina: 6 articles (01/2015 - 01/2015)
4. Briglia, Marilena: 5 articles (01/2015 - 01/2015)
5. Fazio, Antonella: 4 articles (01/2015 - 01/2015)
6. Laufer, Stefan: 3 articles (01/2015 - 01/2015)
7. Officioso, Arbace: 2 articles (08/2015 - 01/2015)
8. Manna, Caterina: 2 articles (08/2015 - 01/2015)
9. Bouguerra, Ghada: 2 articles (01/2015 - 01/2015)
10. Abbès, Salem: 2 articles (01/2015 - 01/2015)

Related Diseases

1. Necrosis
2. Paralysis (Palsy)
3. Inflammation
4. Hemolysis
01/01/2015 - "A 48 hours exposure of human erythrocytes to lopinavir significantly increased the percentage of annexin-V-binding cells (≥ 10 µg/ml), significantly decreased forward scatter (≥15 µg/ml), significantly increased hemolysis (≥ 15 µg/ml), significantly increased Fluo3-fluorescence (20 µg/ml), and significantly increased DCFDA fluorescence (20 µg/ml) but did not significantly modify ceramide abundance. "
01/01/2015 - "A 48 hours exposure of human erythrocytes to fucoxanthin significantly increased the percentage of annexin-V-binding cells (≥ 50 µM), significantly decreased average forward scatter (≥ 25 µM), significantly increased hemolysis (≥ 25 µM), significantly increased Fluo3-fluorescence (≥ 50 µM), significantly increased lipid peroxidation, but did not significantly modify DCFDA fluorescence. "
01/01/2015 - "A 48 hours exposure of human erythrocytes to carnosic acid significantly increased the percentage of annexin-V-binding cells (2.5 µg/ml), significantly decreased forward scatter (10 µg/ml), significantly increased Fluo3 fluorescence (10 µg/ml), significantly increased ceramide abundance (10 µg/ml), significantly increased hemolysis (10 µg/ml), but significantly decreased DCFDA fluorescence (10 µg/ml). "
01/01/2015 - "Phosphatidylserine exposure at the cell surface was estimated from annexin-V-binding, cell volume from forward scatter, hemolysis from hemoglobin release, [Ca2+]i from Fluo3-fluorescence, and ROS formation from DCFDA dependent fluorescence. "
08/01/2015 - "To this end, phosphatidylserine exposure at the cell surface was estimated from annexin-V-binding, cell volume from forward scatter, hemolysis from hemoglobin release, [Ca(2+)]i from Fluo3-fluorescence, and ROS formation from 2',7'-dichlorodihydrofluorescein diacetate (DCFDA) dependent fluorescence. "
5. Fibrosis (Cirrhosis)

Related Drugs and Biologics

1. Adenosine Triphosphate (ATP)
2. 5,5',6,6'- tetrachloro- 1,1',3,3'- tetraethylbenzimidazolocarbocyanine
3. Cardiolipins (Cardiolipin)
4. Antigens
5. Reactive Oxygen Species (Oxygen Radicals)
6. Annexin A5
7. Hemoglobins (Hemoglobin)
8. 2',7'-dichlorodihydrofluorescein diacetate
9. Taurine
10. Bleomycin (Blenoxane)

Related Therapies and Procedures

1. Lasers (Laser)
2. Aftercare (After-Treatment)